Processing

Please wait...

Settings

Settings

1. WO1991001004 - HYBRID MOLECULES

Publication Number WO/1991/001004
Publication Date 24.01.1991
International Application No. PCT/US1990/003828
International Filing Date 06.07.1990
IPC
A61K 47/48 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
48the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C07K 14/55 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins (IL)
55IL-2
C12N 15/62 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
CPC
A61K 47/62
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
C07K 14/55
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins [IL]
55IL-2
C07K 2319/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
Applicants
  • SERAGEN, INC. [US/US]; 97 South Street Hopkinton, MA 01748, US
Inventors
  • SVRLUGA, Richard, C.; US
  • WATERS, Cory, A.; US
Agents
  • FRENCH, Timothy, A.; Fish & Richardson One Financial Center Suite 2500 Boston, MA 02111-2658, US
Priority Data
376,65606.07.1989US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) HYBRID MOLECULES
(FR) MOLECULES HYBRIDES
Abstract
(EN)
A hybrid molecule containing a hematopoietin receptor superfamily cytokine (or a fragment or analog thereof capable of binding to the high-affinity receptor for such cytokine) covalently bonded, at its amino terminal end, to a chemical entity which causes the hybrid molecule to be processed via a lower affinity receptor for such cytokine to a degree less than the degree of processing of the cytokine by the lower affinity receptor, provided that the chemical entity cannot be a fragment of diphtheria toxin which includes the translocation domain of that toxin.
(FR)
Molécule hybride contenant une cytokine de la super famille des récepteurs d'hématopoïétine (ou un fragment ou analogue de celle-ci pouvant se lier au récepteur de grande affinité pour cette cytokine) lié par covalence, à son extrémité terminale amino, à une entité chimique qui provoque le traitement de la molécule hybride via un récepteur d'affinité plus faible pour cette cytokine à un degré moindre que le degré de traitement de la cytokine par le récepteur d'affinité plus faible, à condition que l'entité chimique ne soit pas un fragment de la toxine de la diphtérie qui comprend le domaine de transposition de cette toxine.
Also published as
Latest bibliographic data on file with the International Bureau